Academic Journal
Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells.
| Τίτλος: | Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells. |
|---|---|
| Συγγραφείς: | Batra, Neelu, Tu, Mei-Juan, Guan, Su, Riess, Jonathan W., Yu, Ai-Ming |
| Πηγή: | Non-Coding RNA; Aug2026, Vol. 12 Issue 4, p26, 21p |
| Θεματικοί όροι: | Non-small-cell lung carcinoma, Small interfering RNA, Cancer treatment, Killer cells, Immunotherapy, T cells |
| Περίληψη: | Background/Objectives: Recent advances in immunotherapy have revolutionized cancer treatment, as exemplified by multiple monoclonal antibodies against programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1). Nevertheless, immunotherapeutic antibodies exhibit certain limitations, which drives the development of alternative approaches, such as small interfering RNA (siRNA)-based therapeutics. The aim of this study was to design and produce new biological PD-L1 siRNA (BioRNA/PD-L1-siRNA) molecules and further define their immunotherapeutic efficacy against non-small cell lung cancer (NSCLC) in vitro. Methods: A novel RNA molecular bioengineering platform was employed to produce new BioRNA/PD-L1-siRNA agents. The functions of BioRNA/PD-L1-siRNAs were determined by quantitative PCR, Western blot, immunofluorescence confocal imaging, flow cytometry, and PD-1/PD-L1 blockade assays in human NSCLC cells, alone and co-cultured with human peripheral blood mononuclear cells (PBMCs). Results: After heterologous overexpression and purification of five BioRNA molecules, one siRNA named BioRNA/PD-L1-siRNA-1 was identified as the most effective to selectively suppress human PD-L1 mRNA and protein levels in H460 and H1975 cells. Disruption of PD-1/PD-L1 interactions by BioRNA/PD-L1-siRNA-1 was further demonstrated via a PD-1/PD-L1 blockade bioassay. In addition, the immunomodulatory effectiveness of BioRNA/PD-L1-siRNA-1 was established in co-culture models, as indicated by the induction of T-cell and natural killer cell populations and an increase in specific cytokines and cytotoxic granules, and subsequent enhancement of apoptosis and greater inhibition of NSCLC cell viability. Conclusions: Overall, these findings demonstrate the potential of bioengineered PD-L1 siRNA entities for NSCLC immunotherapy. [ABSTRACT FROM AUTHOR] |
| Copyright of Non-Coding RNA is the property of MDPI and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Βάση Δεδομένων: | Complementary Index |
| FullText | Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:edb&genre=article&issn=2311553X&ISBN=&volume=12&issue=4&date=20260801&spage=26&pages=26-46&title=Non-Coding RNA&atitle=Efficacy%20of%20Bioengineered%20PD-L1%20siRNA%20for%20Immunotherapy%20Against%20Non-Small%20Cell%20Lung%20Cancer%20Cells.&aulast=Batra%2C%20Neelu&id=DOI:10.3390/ncrna12040026 Name: Full Text Finder (for New FTF UI) (ns324271) Category: fullText Text: Full Text Finder MouseOverText: Full Text Finder |
|---|---|
| Header | DbId: edb DbLabel: Complementary Index An: 196614998 RelevancyScore: 1082 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 1082.42456054688 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Batra%2C+Neelu%22">Batra, Neelu</searchLink><br /><searchLink fieldCode="AR" term="%22Tu%2C+Mei-Juan%22">Tu, Mei-Juan</searchLink><br /><searchLink fieldCode="AR" term="%22Guan%2C+Su%22">Guan, Su</searchLink><br /><searchLink fieldCode="AR" term="%22Riess%2C+Jonathan+W%2E%22">Riess, Jonathan W.</searchLink><br /><searchLink fieldCode="AR" term="%22Yu%2C+Ai-Ming%22">Yu, Ai-Ming</searchLink> – Name: TitleSource Label: Source Group: Src Data: Non-Coding RNA; Aug2026, Vol. 12 Issue 4, p26, 21p – Name: Subject Label: Subject Terms Group: Su Data: <searchLink fieldCode="DE" term="%22Non-small-cell+lung+carcinoma%22">Non-small-cell lung carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22Small+interfering+RNA%22">Small interfering RNA</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+treatment%22">Cancer treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Killer+cells%22">Killer cells</searchLink><br /><searchLink fieldCode="DE" term="%22Immunotherapy%22">Immunotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22T+cells%22">T cells</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Background/Objectives: Recent advances in immunotherapy have revolutionized cancer treatment, as exemplified by multiple monoclonal antibodies against programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1). Nevertheless, immunotherapeutic antibodies exhibit certain limitations, which drives the development of alternative approaches, such as small interfering RNA (siRNA)-based therapeutics. The aim of this study was to design and produce new biological PD-L1 siRNA (BioRNA/PD-L1-siRNA) molecules and further define their immunotherapeutic efficacy against non-small cell lung cancer (NSCLC) in vitro. Methods: A novel RNA molecular bioengineering platform was employed to produce new BioRNA/PD-L1-siRNA agents. The functions of BioRNA/PD-L1-siRNAs were determined by quantitative PCR, Western blot, immunofluorescence confocal imaging, flow cytometry, and PD-1/PD-L1 blockade assays in human NSCLC cells, alone and co-cultured with human peripheral blood mononuclear cells (PBMCs). Results: After heterologous overexpression and purification of five BioRNA molecules, one siRNA named BioRNA/PD-L1-siRNA-1 was identified as the most effective to selectively suppress human PD-L1 mRNA and protein levels in H460 and H1975 cells. Disruption of PD-1/PD-L1 interactions by BioRNA/PD-L1-siRNA-1 was further demonstrated via a PD-1/PD-L1 blockade bioassay. In addition, the immunomodulatory effectiveness of BioRNA/PD-L1-siRNA-1 was established in co-culture models, as indicated by the induction of T-cell and natural killer cell populations and an increase in specific cytokines and cytotoxic granules, and subsequent enhancement of apoptosis and greater inhibition of NSCLC cell viability. Conclusions: Overall, these findings demonstrate the potential of bioengineered PD-L1 siRNA entities for NSCLC immunotherapy. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Group: Ab Data: <i>Copyright of Non-Coding RNA is the property of MDPI and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=196614998 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3390/ncrna12040026 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 21 StartPage: 26 Subjects: – SubjectFull: Non-small-cell lung carcinoma Type: general – SubjectFull: Small interfering RNA Type: general – SubjectFull: Cancer treatment Type: general – SubjectFull: Killer cells Type: general – SubjectFull: Immunotherapy Type: general – SubjectFull: T cells Type: general Titles: – TitleFull: Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Batra, Neelu – PersonEntity: Name: NameFull: Tu, Mei-Juan – PersonEntity: Name: NameFull: Guan, Su – PersonEntity: Name: NameFull: Riess, Jonathan W. – PersonEntity: Name: NameFull: Yu, Ai-Ming IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: Aug2026 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 2311553X Numbering: – Type: volume Value: 12 – Type: issue Value: 4 Titles: – TitleFull: Non-Coding RNA Type: main |
| ResultId | 1 |